David Hc King, MD
Urology · Los Gatos
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 22
- 6 carriers
- Office
- 1
Offices
1 location · El Camino Health Medical Network LLC · 202 clinicians in this group
Looking this up.
Hospitals listed: El Camino Health · Good Samaritan Hospital · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
22 plans · 6 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. King’s office at (408) 871-5286 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
22 of 22 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A70154 · Current
Licensed to practise in California · since 1999 · expires 2027-08-31 · University of California, Davis School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$279,576
Medicare paid this office $279,576 for 723 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 320 | $49,004 | $111 |
| Short return visit (20+ min) | 355 | $38,730 | $77 |
| Diagnostic exam of bladder and urethra using an endoscope | 66 | $19,266 | $235 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 13 | $13,533 | None |
| New patient visit (30+ min) | 111 | $10,996 | $99 |
See all 25 services
| Return visit (30+ min) | 320 | $49,004 | $111 |
| Short return visit (20+ min) | 355 | $38,730 | $77 |
| Diagnostic exam of bladder and urethra using an endoscope | 66 | $19,266 | $235 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 13 | $13,533 | None |
| New patient visit (30+ min) | 111 | $10,996 | $99 |
| New patient visit (45+ min) | 72 | $9,803 | $136 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 372 | $7,651 | $15 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 16 | $6,473 | $381 |
| Simple insertion of temporary bladder tube | 22 | $5,496 | $62 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 26 | $4,133 | $153 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 11 | $3,787 | $344 |
| Destruction and/or removal of growth of bladder and urethra using an endoscope, 2.0-5.0 cm | 12 | $2,910 | $242 |
| Short return visit | 42 | $2,742 | $53 |
| Long return visit (40+ min) | 13 | $2,417 | $173 |
| Simple bladder irrigation and/or instillation | 14 | $1,890 | $76 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $1,833 | $71 |
| Injection of drug or substance under skin or into muscle | 16 | $1,678 | $13 |
| Biopsy of prostate gland | 14 | $1,599 | $114 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 50 | $1,598 | $20 |
| Urinalysis, manual test | 237 | $1,357 | $3 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 13 | $1,197 | $37 |
| Ultrasound measurement of bladder capacity after voiding | 60 | $957 | $11 |
| Ultrasound scan of pelvic region through rectum | 11 | $323 | $29 |
| Manual urinalysis test with examination using microscope, non-automated | 48 | $193 | $4 |
| Electronic assessment of bladder emptying | 21 | $179 | $7 |
Procedures Medicare counted
| Prostate resection | 28 | More than 89% of doctors who do this |
Who their Medicare patients are
723 Original Medicare patients in 2024. Average age 77 · Under 65 2% · 85 and older 20% · Women 20% · Also on Medicaid 7% · Health risk score 1.18. At or below the middle of the specialty; the typical urology clinician is at 1.36.
Conditions among them: High blood pressure 75% · Coronary heart disease 36% · Diabetes 29% · Chronic kidney disease 24% · Cancer 23% · Atrial fibrillation 23% · Heart failure 15% · Depression 13% · COPD 10% · Stroke 10% · Dementia 7%.
The office billed $1,168,711, Medicare allowed $372,337 and paid $279,576; for 26,876 services of 86 kinds; $57,741 of it was for drugs given in the office and $221,835 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 723 | 26,876 | 77 | 1.18 | $1,168,711 | $279,576 |
| 2023 | 726 | 19,333 | 77 | 1.12 | $835,166 | $293,770 |
| 2022 | 695 | 16,313 | 77 | 1.16 | $931,799 | $313,914 |
| 2021 | 663 | 15,104 | 77 | 1.22 | $785,391 | $280,642 |
| 2020 | 660 | 17,240 | 77 | 1.34 | $715,269 | $240,365 |
| 2019 | 697 | 23,852 | 76 | 1.20 | $798,733 | $261,225 |
| 2018 | 687 | 18,025 | 77 | 1.34 | $721,797 | $232,342 |
| 2017 | 699 | 4,806 | 77 | 1.30 | $728,301 | $225,129 |
| 2016 | 707 | 2,725 | 77 | 1.35 | $714,987 | $221,163 |
| 2015 | 709 | 3,270 | 77 | 1.33 | $669,354 | $207,339 |
| 2014 | 746 | 3,574 | 77 | 1.23 | $628,382 | $198,884 |
| 2013 | 679 | 3,032 | 77 | 1.19 | $556,439 | $180,538 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 16 services
| Short return visit (20+ min) | 446 | $52,585 | $76 |
| Return visit (30+ min) | 215 | $31,027 | $108 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 22 | $23,101 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 67 | $19,398 | $234 |
| New patient visit (45+ min) | 107 | $14,289 | $134 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 25 | $9,484 | $379 |
| New patient visit (30+ min) | 80 | $7,587 | $95 |
| Simple insertion of temporary bladder tube | 26 | $7,138 | $62 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 40 | $3,303 | $21 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,344 | $156 |
| Insertion of stent in ureter using an endoscope | 13 | $2,186 | $129 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 24 | $2,107 | $35 |
| Ultrasound measurement of bladder capacity after voiding | 97 | $1,446 | $11 |
| Manual urinalysis test with examination using microscope, non-automated | 239 | $1,249 | $4 |
| Short return visit | 22 | $1,091 | $47 |
| Electronic assessment of bladder emptying | 30 | $210 | $7 |
2022: 22 services
| Short return visit (20+ min) | 423 | $49,859 | $77 |
| Return visit (30+ min) | 248 | $36,276 | $107 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 31 | $34,390 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 58 | $17,660 | $242 |
| New patient visit (45+ min) | 113 | $14,659 | $130 |
| Complex measurement of pressure of urine flow in bladder with voiding pressure studies | 27 | $11,474 | $396 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 17 | $11,057 | $650 |
| Complete laser vaporization of prostate including control of bleeding using an endoscope | 15 | $9,430 | $629 |
| New patient visit (30+ min) | 69 | $6,369 | $92 |
| Simple insertion of temporary bladder tube | 21 | $5,654 | $63 |
| Crushing of stone of ureter with insertion of stent using an endoscope | 11 | $3,669 | $334 |
| Biopsy of prostate gland | 13 | $3,183 | $245 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 32 | $2,970 | $34 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 15 | $2,647 | $22 |
| Insertion of stent in ureter using an endoscope | 14 | $2,262 | $133 |
| Short return visit | 31 | $1,653 | $52 |
| Manual urinalysis test with examination using microscope, non-automated | 236 | $1,231 | $4 |
| Ultrasound scan of pelvic region through rectum | 14 | $1,084 | $77 |
| Ultrasound measurement of bladder capacity after voiding | 73 | $973 | $10 |
| Insertion of temporary bladder tube | 13 | $698 | $37 |
| Ultrasonic guidance for needle placement | 13 | $640 | $49 |
| Electronic assessment of bladder emptying | 37 | $295 | $7 |
2021: 15 services
| Short return visit (20+ min) | 352 | $45,675 | $79 |
| Return visit (30+ min) | 223 | $31,003 | $114 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 28 | $27,632 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 84 | $23,863 | $236 |
| New patient visit (45+ min) | 94 | $13,816 | $147 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 12 | $7,918 | $660 |
| New patient visit (30+ min) | 75 | $7,270 | $97 |
| Simple insertion of temporary bladder tube | 18 | $6,416 | $66 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 29 | $5,189 | $179 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 23 | $2,852 | $124 |
| Insertion of stent in ureter using an endoscope | 16 | $2,540 | $121 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 29 | $2,493 | $34 |
| Short return visit | 24 | $1,322 | $53 |
| Manual urinalysis test with examination using microscope, non-automated | 216 | $1,110 | $4 |
| Ultrasound measurement of bladder capacity after voiding | 73 | $1,069 | $11 |
2020: 17 services
| Short return visit (20+ min) | 336 | $33,036 | $63 |
| Return visit (30+ min) | 259 | $32,280 | $92 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 19 | $21,808 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 72 | $18,445 | $205 |
| New patient visit (45+ min) | 89 | $12,541 | $141 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 12 | $8,190 | $682 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 35 | $7,064 | $186 |
| New patient visit (30+ min) | 74 | $6,916 | $93 |
| Simple insertion of temporary bladder tube | 21 | $4,836 | $62 |
| Insertion of stent in ureter using an endoscope | 16 | $2,878 | $144 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 22 | $2,773 | $126 |
| Biopsy of prostate gland | 11 | $2,665 | $242 |
| Short return visit | 44 | $1,866 | $39 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 19 | $1,451 | $30 |
| Biopsy of prostate gland | 12 | $1,387 | $116 |
| Manual urinalysis test with examination using microscope, non-automated | 243 | $1,358 | $4 |
| Ultrasound measurement of bladder capacity after voiding | 89 | $1,281 | $10 |
2019: 18 services
| Return visit (30+ min) | 309 | $37,486 | $90 |
| Short return visit (20+ min) | 328 | $30,625 | $62 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 14 | $18,180 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 73 | $15,826 | $182 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 23 | $15,288 | $665 |
| New patient visit (45+ min) | 108 | $14,308 | $132 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 32 | $5,799 | $181 |
| New patient visit (30+ min) | 54 | $4,700 | $87 |
| Simple insertion of temporary bladder tube | 19 | $3,632 | $55 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 24 | $3,379 | $121 |
| Insertion of stent in ureter using an endoscope | 19 | $3,015 | $126 |
| Short return visit | 57 | $2,593 | $40 |
| Biopsy of prostate gland | 11 | $2,561 | $233 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 11 | $1,575 | $83 |
| Manual urinalysis test with examination using microscope, non-automated | 250 | $1,458 | $4 |
| Ultrasound measurement of bladder capacity after voiding | 80 | $1,299 | $13 |
| Ultrasonic guidance for needle placement | 12 | $555 | $46 |
| Injection of drug or substance under skin or into muscle | 12 | $411 | $16 |
2018: 19 services
| Return visit (30+ min) | 262 | $31,762 | $90 |
| Short return visit (20+ min) | 314 | $28,329 | $60 |
| Diagnostic exam of bladder and urethra using an endoscope | 83 | $17,778 | $156 |
| New patient visit (45+ min) | 111 | $15,672 | $141 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 14 | $12,528 | None |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 18 | $11,947 | $664 |
| New patient visit (30+ min) | 65 | $5,852 | $90 |
| Simple insertion of temporary bladder tube | 22 | $5,789 | $59 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $4,405 | $176 |
| Short return visit | 80 | $3,582 | $39 |
| Biopsy of prostate gland | 14 | $3,449 | $246 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 18 | $2,322 | $122 |
| Insertion of stent in ureter using an endoscope | 15 | $2,321 | $116 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 14 | $2,272 | $81 |
| Ultrasound measurement of bladder capacity after voiding | 100 | $2,205 | $17 |
| Insertion of temporary bladder tube | 20 | $1,578 | $43 |
| Ultrasound scan of pelvic region through rectum | 15 | $1,499 | $94 |
| Manual urinalysis test with examination using microscope, non-automated | 251 | $1,375 | $4 |
| Ultrasonic guidance for needle placement | 14 | $764 | $55 |
2017: 19 services
| Return visit (30+ min) | 265 | $33,378 | $93 |
| Short return visit (20+ min) | 331 | $30,589 | $59 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 17 | $18,454 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 69 | $13,092 | $160 |
| New patient visit (45+ min) | 81 | $11,486 | $142 |
| Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | 14 | $10,633 | $760 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 44 | $8,702 | $181 |
| New patient visit (30+ min) | 73 | $6,473 | $89 |
| Simple insertion of temporary bladder tube | 20 | $5,068 | $56 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 30 | $4,638 | $122 |
| Insertion of stent in ureter using an endoscope | 22 | $3,872 | $138 |
| Simple bladder irrigation and/or instillation | 13 | $3,053 | $68 |
| Short return visit | 67 | $3,021 | $37 |
| Ultrasound measurement of bladder capacity after voiding | 77 | $1,752 | $18 |
| Insertion of temporary bladder tube | 17 | $1,705 | $44 |
| Manual urinalysis test with examination using microscope, non-automated | 253 | $1,414 | $4 |
| Ultrasound scan of pelvic region through rectum | 12 | $1,257 | $97 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 16 | $1,090 | $33 |
| Imaging of urinary tract following injection of a contrast agent | 14 | $273 | $16 |
2016: 22 services
| Short return visit (20+ min) | 412 | $36,345 | $58 |
| Return visit (30+ min) | 239 | $27,814 | $89 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 23 | $26,472 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 69 | $16,657 | $179 |
| New patient visit (45+ min) | 83 | $11,302 | $136 |
| Simple insertion of temporary bladder tube | 23 | $7,491 | $62 |
| New patient visit (30+ min) | 69 | $5,982 | $87 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 28 | $5,097 | $170 |
| Biopsy of prostate gland | 19 | $3,790 | $199 |
| Short return visit | 80 | $2,996 | $34 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 17 | $2,217 | $117 |
| Ultrasound measurement of bladder capacity after voiding | 82 | $1,954 | $18 |
| Ultrasound scan of pelvic region through rectum | 21 | $1,911 | $91 |
| Manual urinalysis test with examination using microscope, non-automated | 266 | $1,515 | $4 |
| Ultrasonic guidance for needle placement | 22 | $1,357 | $57 |
| Insertion of temporary bladder tube | 18 | $1,284 | $43 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 23 | $1,259 | $29 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 11 | $798 | $17 |
| New patient visit (15+ min) | 12 | $613 | $51 |
| Immunologic analysis for detection of tumor antigen, qualitative or semiquantitative | 13 | $472 | $26 |
| Imaging of urinary tract following injection of a contrast agent | 13 | $246 | $15 |
| Electronic assessment of bladder emptying | 11 | $116 | $11 |
2015: 23 services
| Short return visit (20+ min) | 410 | $37,931 | $61 |
| Return visit (30+ min) | 254 | $29,842 | $92 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 20 | $20,095 | None |
| Diagnostic exam of bladder and urethra using an endoscope | 55 | $14,130 | $188 |
| New patient visit (45+ min) | 84 | $11,503 | $137 |
| New patient visit (30+ min) | 94 | $8,063 | $86 |
| Simple insertion of temporary bladder tube | 25 | $7,277 | $69 |
| Shock wave crushing of kidney stones | 11 | $6,642 | $553 |
| Simple change of bladder tube | 11 | $5,257 | $80 |
| Short return visit | 70 | $3,248 | $39 |
| Ultrasound measurement of bladder capacity after voiding | 107 | $2,595 | $18 |
| Biopsy of prostate gland | 11 | $2,261 | $206 |
| Manual urinalysis test with examination using microscope, non-automated | 305 | $1,808 | $4 |
| Insertion of stent in ureter using an endoscope | 16 | $1,783 | $94 |
| Insertion of temporary bladder tube | 27 | $1,748 | $50 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $1,382 | $92 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 21 | $1,169 | $32 |
| Ultrasound scan of pelvic region through rectum | 12 | $1,118 | $93 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,090 | $64 |
| Ultrasonic guidance for needle placement | 12 | $691 | $58 |
| New patient visit (15+ min) | 11 | $616 | $56 |
| Imaging of urinary tract following injection of a contrast agent | 26 | $511 | $16 |
| Immunologic analysis for detection of tumor antigen, qualitative or semiquantitative | 14 | $497 | $26 |
2014: 17 services
| Short return visit (20+ min) | 438 | $42,111 | $61 |
| Return visit (30+ min) | 180 | $19,371 | $92 |
| Diagnostic exam of bladder and urethra using an endoscope | 72 | $16,703 | $180 |
| New patient visit (30+ min) | 147 | $12,314 | $84 |
| Short return visit | 138 | $7,336 | $37 |
| New patient visit (45+ min) | 49 | $6,871 | $140 |
| Simple insertion of temporary bladder tube | 21 | $3,942 | $66 |
| Ultrasound measurement of bladder capacity after voiding | 116 | $3,103 | $18 |
| Insertion of stent in ureter using an endoscope | 20 | $2,753 | $102 |
| Insertion of temporary bladder tube | 31 | $2,091 | $48 |
| Manual urinalysis test with examination using microscope, non-automated | 301 | $1,857 | $4 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $1,751 | $92 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 24 | $1,665 | $64 |
| New patient visit (15+ min) | 32 | $1,653 | $52 |
| Imaging of urinary tract following injection of a contrast agent | 20 | $423 | $16 |
| Immunologic analysis for detection of tumor antigen, qualitative or semiquantitative | 11 | $333 | $24 |
| Electronic assessment of bladder emptying | 16 | $163 | $10 |
2013: 18 services
| Short return visit (20+ min) | 366 | $34,503 | $62 |
| Return visit (30+ min) | 145 | $14,818 | $89 |
| New patient visit (30+ min) | 147 | $13,667 | $93 |
| Diagnostic exam of bladder and urethra using an endoscope | 58 | $13,104 | $182 |
| Short return visit | 187 | $10,002 | $38 |
| Complete laser vaporization of prostate including control of bleeding using an endoscope | 15 | $8,962 | $597 |
| New patient visit (45+ min) | 42 | $6,092 | $145 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $3,941 | $171 |
| Simple insertion of temporary bladder tube | 22 | $3,864 | $68 |
| Ultrasonic guidance for needle placement | 11 | $2,785 | $214 |
| Ultrasound measurement of bladder capacity after voiding | 90 | $2,579 | $19 |
| Simple bladder irrigation and/or instillation | 11 | $2,079 | $74 |
| Insertion of temporary bladder tube | 26 | $1,885 | $48 |
| New patient visit (15+ min) | 23 | $1,546 | $67 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $940 | $63 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 12 | $757 | $33 |
| Manual urinalysis test with examination using microscope, non-automated | 54 | $248 | $4 |
| Electronic assessment of bladder emptying | 14 | $156 | $10 |
Drugs they prescribed that Part D paid
$436,047
Pharmacies billed $436,047 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 2% of their Part D prescriptions (38 of 2,389) in 2024. At or below the middle of the specialty; the typical urology clinician is at 2%.
2,110 generic and fewer than 11 brand-name prescriptions · $436,047 in drug cost · 417 antibiotic prescriptions to 215 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Xtandi | 12 | $167,562 | $13,964 |
| Gemtesa | 135 | $111,404 | $825 |
| Myrbetriq | 86 | $62,811 | $730 |
| Elmiron | 12 | $28,987 | $2,416 |
| Tamsulosin | 773 | $15,872 | $21 |
See all 30 drugs
| Xtandi | 12 | $167,562 | $13,964 |
| Gemtesa | 135 | $111,404 | $825 |
| Myrbetriq | 86 | $62,811 | $730 |
| Elmiron | 12 | $28,987 | $2,416 |
| Tamsulosin | 773 | $15,872 | $21 |
| Testosterone | 40 | $5,427 | $136 |
| Finasteride | 265 | $5,228 | $20 |
| Methenamine Hippurate | 58 | $4,447 | $77 |
| Tadalafil | 19 | $3,636 | $191 |
| Testosterone Cypionate | 42 | $2,503 | $60 |
| Estradiol | 35 | $2,418 | $69 |
| Nitrofurantoin | 69 | $2,106 | $31 |
| Dutasteride | 55 | $1,873 | $34 |
| Oxybutynin Chloride Er | 78 | $1,801 | $23 |
| Silodosin | 18 | $1,731 | $96 |
| Doxazosin Mesylate | 57 | $1,535 | $27 |
| Alfuzosin Hcl Er | 46 | $725 | $16 |
| Bicalutamide | 19 | $717 | $38 |
| Desmopressin Acetate | 22 | $663 | $30 |
| Cephalexin | 107 | $446 | $4 |
| Sulfamethoxazole-Trimethoprim | 52 | $433 | $8 |
| Amoxicillin-Clavulanate Potass | 37 | $354 | $10 |
| Ciprofloxacin | 72 | $346 | $5 |
| Allopurinol | 15 | $277 | $18 |
| Nitrofurantoin Mono-Macro | 16 | $272 | $17 |
| Cefuroxime | 28 | $263 | $9 |
| Levofloxacin | 22 | $155 | $7 |
| Hydrocodone-Acetaminophen | 19 | $118 | $6 |
| Fluconazole | 11 | $49 | $4 |
| Hydromorphone | 12 | $27 | $2 |
Year by year
| 2024 | 2,389 | 631 | 2% (38) | None | $436,047 |
| 2023 | 2,393 | 555 | 2% (46) | None | $692,465 |
| 2022 | 2,117 | 502 | 2% (36) | None | $561,887 |
| 2021 | 2,095 | 503 | 2% (42) | 14% | $185,344 |
| 2020 | 2,110 | 467 | 2% (37) | None | $253,266 |
| 2019 | 2,121 | 471 | 3% (64) | None | $191,936 |
| 2018 | 2,236 | 474 | 2% (53) | None | $256,857 |
| 2017 | 2,316 | 458 | 1% (26) | None | $249,236 |
| 2016 | 2,387 | 452 | 2% (46) | None | $249,053 |
| 2015 | 2,089 | 447 | 2% (32) | None | $214,292 |
| 2014 | 2,144 | 445 | 1% (29) | 28% | $212,067 |
| 2013 | 1,788 | 376 | 2% (33) | None | $147,854 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 29 drugs
| Xtandi | 29 | $430,489 | $14,844 |
| Gemtesa | 115 | $89,775 | $781 |
| Myrbetriq | 114 | $74,404 | $653 |
| Elmiron | 14 | $24,405 | $1,743 |
| Tamsulosin | 766 | $19,608 | $26 |
| Testosterone | 44 | $9,265 | $211 |
| Finasteride | 226 | $4,590 | $20 |
| Dutasteride | 61 | $3,899 | $64 |
| Oxybutynin Chloride Er | 100 | $3,661 | $37 |
| Methenamine Hippurate | 41 | $3,575 | $87 |
| Estradiol | 30 | $3,043 | $101 |
| Silodosin | 15 | $2,275 | $152 |
| Desmopressin Acetate | 18 | $2,255 | $125 |
| Nitrofurantoin | 64 | $2,007 | $31 |
| Testosterone Cypionate | 45 | $1,994 | $44 |
| Alfuzosin Hcl Er | 40 | $1,728 | $43 |
| Tadalafil | 29 | $1,499 | $52 |
| Doxazosin Mesylate | 53 | $1,282 | $24 |
| Solifenacin | 17 | $979 | $58 |
| Bicalutamide | 19 | $680 | $36 |
| Cephalexin | 104 | $638 | $6 |
| Nitrofurantoin Mono-Macro | 25 | $560 | $22 |
| Sulfamethoxazole-Trimethoprim | 54 | $538 | $10 |
| Cefuroxime | 25 | $452 | $18 |
| Amoxicillin-Clavulanate Potass | 35 | $361 | $10 |
| Ciprofloxacin | 51 | $323 | $6 |
| Levofloxacin | 32 | $235 | $7 |
| Hydrocodone-Acetaminophen | 33 | $189 | $6 |
| Triamcinolone Acetonide | 13 | $49 | $4 |
2022: 30 drugs
| Xtandi | 25 | $358,514 | $14,341 |
| Myrbetriq | 177 | $96,769 | $547 |
| Gemtesa | 44 | $26,449 | $601 |
| Tamsulosin | 658 | $14,733 | $22 |
| Methenamine Hippurate | 44 | $4,895 | $111 |
| Testosterone | 27 | $4,778 | $177 |
| Finasteride | 222 | $4,492 | $20 |
| Oxybutynin Chloride Er | 77 | $4,036 | $52 |
| Estradiol | 23 | $2,925 | $127 |
| Dutasteride | 45 | $2,482 | $55 |
| Silodosin | 25 | $1,939 | $78 |
| Alfuzosin Hcl Er | 43 | $1,827 | $42 |
| Tadalafil | 37 | $1,754 | $47 |
| Doxazosin Mesylate | 64 | $1,497 | $23 |
| Nitrofurantoin | 34 | $1,458 | $43 |
| Testosterone Cypionate | 19 | $1,350 | $71 |
| Solifenacin | 12 | $1,104 | $92 |
| Bicalutamide | 13 | $663 | $51 |
| Cephalexin | 91 | $434 | $5 |
| Terazosin | 11 | $414 | $38 |
| Sulfamethoxazole-Trimethoprim | 50 | $406 | $8 |
| Nitrofurantoin Mono-Macro | 21 | $396 | $19 |
| Cefuroxime | 21 | $373 | $18 |
| Ciprofloxacin | 65 | $305 | $5 |
| Hydrocodone-Acetaminophen | 29 | $183 | $6 |
| Allopurinol | 17 | $177 | $10 |
| Levofloxacin | 26 | $144 | $6 |
| Amoxicillin-Clavulanate Potass | 18 | $106 | $6 |
| Imipramine | 12 | $82 | $7 |
| Triamcinolone Acetonide | 11 | $19 | $2 |
2021: 28 drugs
| Myrbetriq | 188 | $104,090 | $554 |
| Tamsulosin | 705 | $15,305 | $22 |
| Elmiron | 11 | $9,235 | $840 |
| Testosterone | 35 | $6,316 | $180 |
| Oxybutynin Chloride Er | 99 | $4,980 | $50 |
| Finasteride | 207 | $4,598 | $22 |
| Tadalafil | 29 | $4,369 | $151 |
| Nitrofurantoin | 51 | $2,824 | $55 |
| Estradiol | 27 | $2,460 | $91 |
| Doxazosin Mesylate | 63 | $2,388 | $38 |
| Methenamine Hippurate | 25 | $2,339 | $94 |
| Testosterone Cypionate | 28 | $2,211 | $79 |
| Renacidin | 12 | $2,090 | $174 |
| Dutasteride | 34 | $2,086 | $61 |
| Alfuzosin Hcl Er | 61 | $1,915 | $31 |
| Silodosin | 19 | $1,218 | $64 |
| Nitrofurantoin Mono-Macro | 30 | $665 | $22 |
| Bicalutamide | 13 | $556 | $43 |
| Cephalexin | 87 | $393 | $5 |
| Sulfamethoxazole-Trimethoprim | 41 | $298 | $7 |
| Ciprofloxacin | 65 | $271 | $4 |
| Levofloxacin | 28 | $244 | $9 |
| Oxybutynin Chloride | 11 | $222 | $20 |
| Allopurinol | 18 | $157 | $9 |
| Hydrocodone-Acetaminophen | 26 | $136 | $5 |
| Amoxicillin-Clavulanate Potass | 12 | $122 | $10 |
| Imipramine | 12 | $105 | $9 |
| Oxycodone-Acetaminophen | 11 | $75 | $7 |
2020: 29 drugs
| Myrbetriq | 187 | $100,909 | $540 |
| Toviaz | 37 | $16,725 | $452 |
| Tamsulosin | 689 | $15,039 | $22 |
| Elmiron | 17 | $13,829 | $813 |
| Tadalafil | 28 | $7,747 | $277 |
| Testosterone | 31 | $6,864 | $221 |
| Oxybutynin Chloride Er | 118 | $6,465 | $55 |
| Doxazosin Mesylate | 72 | $4,328 | $60 |
| Finasteride | 162 | $4,172 | $26 |
| Estradiol | 19 | $2,906 | $153 |
| Dutasteride | 39 | $2,824 | $72 |
| Testosterone Cypionate | 23 | $1,955 | $85 |
| Nitrofurantoin | 45 | $1,894 | $42 |
| Alfuzosin Hcl Er | 71 | $1,884 | $27 |
| Methenamine Hippurate | 19 | $1,633 | $86 |
| Nitrofurantoin Mono-Macro | 32 | $863 | $27 |
| Ciprofloxacin | 88 | $609 | $7 |
| Terazosin | 14 | $504 | $36 |
| Oxybutynin Chloride | 15 | $418 | $28 |
| Bicalutamide | 14 | $393 | $28 |
| Sulfamethoxazole-Trimethoprim | 46 | $329 | $7 |
| Cephalexin | 66 | $287 | $4 |
| Levofloxacin | 26 | $241 | $9 |
| Amoxicillin-Clavulanate Potass | 18 | $200 | $11 |
| Imipramine | 13 | $153 | $12 |
| Hydrocodone-Acetaminophen | 25 | $120 | $5 |
| Allopurinol | 17 | $101 | $6 |
| Fluconazole | 13 | $79 | $6 |
| Triamcinolone Acetonide | 11 | $37 | $3 |
2019: 30 drugs
| Myrbetriq | 137 | $71,627 | $523 |
| Elmiron | 14 | $17,498 | $1,250 |
| Tamsulosin | 611 | $14,206 | $23 |
| Tadalafil | 34 | $11,010 | $324 |
| Vesicare | 14 | $7,280 | $520 |
| Toviaz | 16 | $7,034 | $440 |
| Oxybutynin Chloride Er | 112 | $6,824 | $61 |
| Doxazosin Mesylate | 86 | $6,057 | $70 |
| Finasteride | 231 | $5,684 | $25 |
| Testosterone | 21 | $5,265 | $251 |
| Dutasteride | 40 | $3,233 | $81 |
| Estradiol | 12 | $2,169 | $181 |
| Nitrofurantoin | 45 | $1,757 | $39 |
| Testosterone Cypionate | 18 | $1,580 | $88 |
| Alfuzosin Hcl Er | 49 | $1,195 | $24 |
| Oxybutynin Chloride | 28 | $1,031 | $37 |
| Nitrofurantoin Mono-Macro | 49 | $1,024 | $21 |
| Bicalutamide | 18 | $599 | $33 |
| Ciprofloxacin | 70 | $481 | $7 |
| Cephalexin | 84 | $473 | $6 |
| Hydrocodone-Acetaminophen | 48 | $324 | $7 |
| Sulfamethoxazole-Trimethoprim | 45 | $309 | $7 |
| Cefuroxime | 13 | $258 | $20 |
| Amoxicillin-Clavulanate Potass | 27 | $254 | $9 |
| Terazosin | 19 | $225 | $12 |
| Levofloxacin | 21 | $174 | $8 |
| Imipramine | 12 | $137 | $11 |
| Losartan | 16 | $127 | $8 |
| Escitalopram | 11 | $91 | $8 |
| Alprazolam | 13 | $54 | $4 |
2018: 30 drugs
| Myrbetriq | 153 | $74,714 | $488 |
| Androgel | 28 | $33,552 | $1,198 |
| Vesicare | 39 | $20,671 | $530 |
| Cialis | 27 | $20,351 | $754 |
| Elmiron | 15 | $16,725 | $1,115 |
| Tamsulosin | 661 | $15,758 | $24 |
| Testosterone | 17 | $8,746 | $514 |
| Premarin | 21 | $7,783 | $371 |
| Rapaflo | 25 | $7,393 | $296 |
| Doxazosin Mesylate | 107 | $6,509 | $61 |
| Finasteride | 319 | $6,025 | $19 |
| Oxybutynin Chloride Er | 83 | $5,978 | $72 |
| Toviaz | 11 | $3,600 | $327 |
| Dutasteride | 27 | $2,766 | $102 |
| Methenamine Hippurate | 13 | $1,565 | $120 |
| Testosterone Cypionate | 24 | $1,548 | $64 |
| Alfuzosin Hcl Er | 57 | $1,359 | $24 |
| Nitrofurantoin | 34 | $1,288 | $38 |
| Oxybutynin Chloride | 35 | $1,278 | $37 |
| Nitrofurantoin Mono-Macro | 29 | $808 | $28 |
| Bicalutamide | 42 | $774 | $18 |
| Ciprofloxacin | 102 | $733 | $7 |
| Hydrocodone-Acetaminophen | 43 | $278 | $6 |
| Sulfamethoxazole-Trimethoprim | 45 | $266 | $6 |
| Cefuroxime | 14 | $253 | $18 |
| Terazosin | 19 | $231 | $12 |
| Amoxicillin-Clavulanate Potass | 24 | $216 | $9 |
| Cephalexin | 35 | $207 | $6 |
| Allopurinol | 12 | $170 | $14 |
| Imipramine | 12 | $62 | $5 |
2017: 29 drugs
| Myrbetriq | 138 | $57,562 | $417 |
| Androgel | 39 | $36,349 | $932 |
| Vesicare | 59 | $26,303 | $446 |
| Cialis | 38 | $23,202 | $611 |
| Tamsulosin | 703 | $17,329 | $25 |
| Rapaflo | 37 | $8,375 | $226 |
| Premarin | 18 | $6,945 | $386 |
| Doxazosin Mesylate | 140 | $5,361 | $38 |
| Oxybutynin Chloride Er | 86 | $5,292 | $62 |
| Finasteride | 314 | $4,886 | $16 |
| Potassium Citrate Er | 24 | $3,844 | $160 |
| Tolterodine | 24 | $2,935 | $122 |
| Oxybutynin Chloride | 40 | $1,544 | $39 |
| Testosterone Cypionate | 25 | $1,430 | $57 |
| Nitrofurantoin | 26 | $1,282 | $49 |
| Nitrofurantoin Mono-Macro | 34 | $1,026 | $30 |
| Alfuzosin Hcl Er | 60 | $1,010 | $17 |
| Dutasteride | 16 | $790 | $49 |
| Ciprofloxacin | 69 | $440 | $6 |
| Bicalutamide | 18 | $426 | $24 |
| Amoxicillin-Clavulanate Potass | 31 | $379 | $12 |
| Sulfamethoxazole-Trimethoprim | 53 | $364 | $7 |
| Glycopyrrolate | 11 | $305 | $28 |
| Cephalexin | 39 | $232 | $6 |
| Allopurinol | 13 | $130 | $10 |
| Levofloxacin | 12 | $125 | $10 |
| Hydrocodone-Acetaminophen | 24 | $116 | $5 |
| Terazosin | 15 | $112 | $7 |
| Hydrochlorothiazide | 17 | $30 | $2 |
2016: 33 drugs
| Myrbetriq | 152 | $54,148 | $356 |
| Vesicare | 93 | $32,284 | $347 |
| Cialis | 53 | $23,453 | $443 |
| Androgel | 29 | $19,541 | $674 |
| Tamsulosin | 667 | $17,237 | $26 |
| Rapaflo | 67 | $14,482 | $216 |
| Casodex | 13 | $6,840 | $526 |
| Premarin | 19 | $5,748 | $303 |
| Oxybutynin Chloride Er | 94 | $4,750 | $51 |
| Toviaz | 14 | $4,497 | $321 |
| Finasteride | 271 | $3,996 | $15 |
| Doxazosin Mesylate | 103 | $3,774 | $37 |
| Potassium Citrate Er | 29 | $3,706 | $128 |
| Tolterodine Tartrate Er | 18 | $3,628 | $202 |
| Dutasteride-Tamsulosin | 14 | $3,115 | $223 |
| Tolterodine | 16 | $2,044 | $128 |
| Alfuzosin Hcl Er | 72 | $1,345 | $19 |
| Testosterone Cypionate | 18 | $1,177 | $65 |
| Nitrofurantoin | 31 | $1,142 | $37 |
| Ciprofloxacin | 108 | $908 | $8 |
| Nitrofurantoin Mono-Macro | 24 | $788 | $33 |
| Oxybutynin Chloride | 37 | $734 | $20 |
| Sulfamethoxazole-Trimethoprim | 85 | $718 | $8 |
| Bicalutamide | 32 | $639 | $20 |
| Amoxicillin-Clavulanate Potass | 33 | $403 | $12 |
| Allopurinol | 12 | $331 | $28 |
| Hydrocodone-Acetaminophen | 35 | $293 | $8 |
| Imipramine | 21 | $221 | $11 |
| Cephalexin | 24 | $214 | $9 |
| Levofloxacin | 11 | $154 | $14 |
| Terazosin | 11 | $135 | $12 |
| Alprazolam | 11 | $78 | $7 |
| Hydrochlorothiazide | 14 | $37 | $3 |
2015: 27 drugs
| Myrbetriq | 118 | $39,475 | $335 |
| Vesicare | 123 | $37,343 | $304 |
| Rapaflo | 89 | $19,636 | $221 |
| Tamsulosin | 510 | $16,866 | $33 |
| Cialis | 44 | $14,025 | $319 |
| Androgel | 18 | $8,256 | $459 |
| Oxybutynin Chloride Er | 95 | $5,483 | $58 |
| Jalyn | 18 | $5,459 | $303 |
| Toviaz | 14 | $4,989 | $356 |
| Premarin | 17 | $4,376 | $257 |
| Doxazosin Mesylate | 60 | $3,454 | $58 |
| Tolterodine | 11 | $2,934 | $267 |
| Finasteride | 189 | $2,595 | $14 |
| Alfuzosin Hcl Er | 104 | $1,885 | $18 |
| Nitrofurantoin | 37 | $1,322 | $36 |
| Oxybutynin Chloride | 42 | $983 | $23 |
| Testosterone Cypionate | 14 | $961 | $69 |
| Bicalutamide | 42 | $918 | $22 |
| Ciprofloxacin | 115 | $673 | $6 |
| Nitrofurantoin Mono-Macro | 25 | $645 | $26 |
| Amoxicillin-Clavulanate Potass | 37 | $476 | $13 |
| Sulfamethoxazole-Trimethoprim | 77 | $407 | $5 |
| Imipramine | 22 | $348 | $16 |
| Levofloxacin | 20 | $196 | $10 |
| Hydrocodone-Acetaminophen | 25 | $160 | $6 |
| Cephalexin | 25 | $145 | $6 |
| Alprazolam | 12 | $52 | $4 |
2014: 31 drugs
| Vesicare | 104 | $33,810 | $325 |
| Androgel | 36 | $18,150 | $504 |
| Cialis | 65 | $16,785 | $258 |
| Myrbetriq | 50 | $16,638 | $333 |
| Elmiron | 11 | $15,422 | $1,402 |
| Rapaflo | 81 | $14,143 | $175 |
| Tamsulosin | 531 | $11,540 | $22 |
| Avodart | 64 | $11,540 | $180 |
| Premarin | 29 | $7,326 | $253 |
| Oxybutynin Chloride Er | 124 | $7,210 | $58 |
| Jalyn | 14 | $4,733 | $338 |
| Gelnique | 20 | $4,642 | $232 |
| Enablex | 20 | $4,080 | $204 |
| Toviaz | 19 | $3,638 | $191 |
| Trospium Chloride Er | 13 | $3,473 | $267 |
| Doxazosin Mesylate | 60 | $2,891 | $48 |
| Alfuzosin Hcl Er | 123 | $2,851 | $23 |
| Tolterodine | 11 | $2,627 | $239 |
| Finasteride | 148 | $2,440 | $16 |
| Nitrofurantoin | 50 | $1,778 | $36 |
| Nitrofurantoin Mono-Macro | 42 | $1,340 | $32 |
| Methenamine Hippurate | 11 | $702 | $64 |
| Ciprofloxacin | 123 | $670 | $5 |
| Bicalutamide | 17 | $603 | $35 |
| Oxybutynin Chloride | 20 | $567 | $28 |
| Sulfamethoxazole-Trimethoprim | 86 | $530 | $6 |
| Amox Tr-Potassium Clavulanate | 31 | $505 | $16 |
| Cefuroxime | 14 | $502 | $36 |
| Hydrocodone-Acetaminophen | 20 | $351 | $18 |
| Imipramine | 11 | $162 | $15 |
| Cephalexin | 23 | $155 | $7 |
2013: 29 drugs
| Vesicare | 97 | $24,995 | $258 |
| Androgel | 33 | $17,987 | $545 |
| Avodart | 82 | $11,637 | $142 |
| Tamsulosin | 432 | $9,294 | $22 |
| Oxybutynin Chloride Er | 101 | $6,443 | $64 |
| Premarin | 22 | $5,370 | $244 |
| Toviaz | 27 | $5,327 | $197 |
| Myrbetriq | 24 | $5,278 | $220 |
| Alfuzosin | 112 | $5,233 | $47 |
| Trospium Chloride Er | 20 | $4,117 | $206 |
| Gelnique | 20 | $3,811 | $191 |
| Enablex | 22 | $3,799 | $173 |
| Finasteride | 111 | $3,482 | $31 |
| Jalyn | 16 | $3,179 | $199 |
| Rapaflo | 22 | $3,157 | $143 |
| Cialis | 13 | $2,950 | $227 |
| Doxazosin Mesylate | 70 | $1,974 | $28 |
| Nitrofurantoin | 50 | $1,933 | $39 |
| Methenamine Hippurate | 14 | $1,484 | $106 |
| Nitrofurantoin Mono-Macro | 31 | $1,201 | $39 |
| Glycopyrrolate | 14 | $812 | $58 |
| Bicalutamide | 20 | $768 | $38 |
| Ciprofloxacin | 104 | $636 | $6 |
| Sulfamethoxazole-Trimethoprim | 61 | $337 | $6 |
| Cefuroxime | 13 | $213 | $16 |
| Cephalexin | 29 | $195 | $7 |
| Hydrocodone-Acetaminophen | 23 | $184 | $8 |
| Levofloxacin | 11 | $95 | $9 |
| Amoxicillin | 12 | $68 | $6 |
Money from drug and device companies
$805 in 2025
| 2025 | 5 | 18 | None | $805 |
| 2024 | 7 | 13 | None | $406 |
| 2023 | 5 | 18 | None | $322 |
| 2022 | 4 | 20 | None | $355 |
| 2021 | 4 | 6 | None | $166 |
| 2020 | 5 | 16 | None | $378 |
| 2019 | 7 | 49 | None | $797 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Procept Biorobotics | Aquabeam Robotic System | $592 | 9 payments
|
| Sumitomo Pharma America | Gemtesa | $79 | 4 payments
|
| Accord Healthcare | Camcevi | $64 | 3 payments
|
| Pfizer | Xtandi | $38 | 1 payment
|
| Verity Pharmaceuticals | Tlando | $32 | 1 payment
|
See all 18 published payments
| Procept Biorobotics | Meals · 2025-12-22 | Aquabeam Robotic System | $18 |
| Procept Biorobotics | Meals · 2025-11-26 | Aquabeam Robotic System | $12 |
| Sumitomo Pharma America | Meals · 2025-11-04 | Gemtesa | $18 |
| Sumitomo Pharma America | Meals · 2025-10-23 | Gemtesa | $18 |
| Procept Biorobotics | Meals · 2025-10-20 | Aquabeam Robotic System | $10 |
| Procept Biorobotics | Meals · 2025-09-30 | Aquabeam Robotic System | $27 |
| Accord Healthcare | Meals · 2025-08-12 | Camcevi | $23 |
| Accord Healthcare | Meals · 2025-06-23 | Camcevi | $23 |
| Sumitomo Pharma America | Meals · 2025-06-03 | Gemtesa | $17 |
| Pfizer | Meals · 2025-04-17 | Xtandi | $38 |
| Accord Healthcare | Meals · 2025-03-28 | Camcevi | $19 |
| Sumitomo Pharma America | Meals · 2025-02-27 | Gemtesa | $26 |
| Verity Pharmaceuticals | Meals · 2025-02-26 | Tlando | $32 |
| Procept Biorobotics | Travel · 2025-02-22 | Aquabeam Robotic System | $260 |
| Procept Biorobotics | Meals · 2025-02-22 | Aquabeam Robotic System | $143 |
| Procept Biorobotics | Meals · 2025-02-22 | Aquabeam Robotic System | $36 |
| Procept Biorobotics | Meals · 2025-02-22 | Aquabeam Robotic System | $59 |
| Procept Biorobotics | Meals · 2025-02-22 | Aquabeam Robotic System | $29 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $406
| Medtronic | Interstim | $115 | 1 payment
|
| Sumitomo Pharma America | Gemtesa | $76 | 2 payments
|
| Astellas Pharma US | Xtandi | $73 | 4 payments
|
| Janssen Biotech | Erleada | $51 | 2 payments
|
| Bluewind Medical | Revi | $39 | 2 payments
|
| Progenics Pharmaceuticals | Pylarify | $30 | 1 payment
|
| Laborie Medical Technologies | Eclipse | $22 | 1 payment
|
2023: $322
| Astellas Pharma US | Myrbetriq | $191 | 13 payments
|
| Pfizer | Xtandi | $43 | 2 payments
|
| Teleflex | Urolift | $36 | 1 payment
|
| Progenics Pharmaceuticals | Pylarify | $26 | 1 payment
|
| Janssen Biotech | Erleada | $25 | 1 payment
|
2022: $355
| Astellas Pharma US | Myrbetriq | $285 | 16 payments
|
| Janssen Biotech | Erleada | $30 | 2 payments
|
| Abbvie | Lupron Depot | $27 | 1 payment
|
| Pfizer | Premarin | $12 | 1 payment
|
2021: $166
| PROCEPT BioRobotics | Aquabeam Robotic System | $84 | 2 payments
|
| Astellas Pharma US | Xtandi | $38 | 2 payments
|
| SRS Medical Systems | Urocuff | $28 | 1 payment
|
| 180 Medical | Gentlecath | $17 | 1 payment
|
2020: $378
| Astellas Pharma US | Vesicare | $243 | 9 payments
|
| Pfizer | Xtandi | $92 | 4 payments
|
| Photocure | Cysview | $15 | 1 payment
|
| Janssen Biotech | Erleada | $14 | 1 payment
|
| Amgen | Prolia | $14 | 1 payment
|
2019: $797
| Pfizer | Xtandi | $198 | 22 payments
|
| Allergan | Botox | $172 | 4 payments
|
| Janssen Biotech | Erleada | $167 | 15 payments
|
| Astellas Pharma US | Xtandi | $143 | 4 payments
|
| Dendreon Pharmaceuticals | Provenge | $60 | 2 payments
|
| PROCEPT BioRobotics | Aquabeam Robotic System | $34 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $23 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1578507083
- Licence
- CA A70154California A70154: Current · expires 2027-08-31
- Trained
- University of California, Davis School of Medicine, 1990
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Urology (208800000X)
- Mailing address
- 320 Dardanelli Ln, Suite 23b, Los Gatos, CA, 95032
- NPI first listed
- 2006-06-15
- NPI last updated
- 2008-10-15
This is when the NPI record was last certified, not a medical board exam.